Scott Weiner

Scott joined Amzak Health in 2020 and leads the Firm’s activities to expand and manage its biotech portfolio.  Prior to that he was a Partner at Pappas Capital where he spent 13 years focused on life science venture investing.  Scott was previously an investment manager and research analyst for Silverback Asset Management’s life science fund where he focused on healthcare securities investing.  Before joining Silverback, he spent three years at Chicago Growth Partners focused on healthcare venture investments, and prior to that, he spent three and a half years in investment backing at Lehman Brothers where he worked in New York, London and Hong Kong.

Scott has been a buy side investor in the life science sector for over 18 years and has been involved in over 30 venture transactions including 4D Molecular Therapeutics (NASDAQ: FDMT), Achillion (NASDAQ: ACHN, acquired by Alexion), Inhibitex (NASDAQ: INHX, acquired by Bristol-Myers Squibb), Milestone Pharmaceuticals (NASDAQ: MIST), Plexxikon (acquired by Daiichi Sankyo), Rotation Medical (acquired by Smith & Nephew), TESARO (NASDAQ: TSRO, acquired by GSK) and VelosBio (acquired by Merck).